Obsidian Therapeutics Raises $160.5M in Series C Financing precisionmedicineonline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from precisionmedicineonline.com Daily Mail and Mail on Sunday newspapers.
The tumor-infiltrating lymphocyte cell therapy OBX-115 produced responses with no dose-limiting toxicities in heavily pretreated patients with advanced or metastatic melanoma whose who had progressed on anti–PD-1 and anti–CTLA-4 therapy with disease that was primary-resistant to immune checkpoint inhibitor therapy.